Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s rogue exec strikes back

Executive Summary

Peter Rost files a wrongful termination suit against Pfizer, CEO Hank McKinnell and other senior executives Dec. 12. Rost's suit alleges the defendants violated the N.J. Conscientious Employee Protection Act, which prohibits companies from retaliating against whistleblowers. Pfizer terminated Rost, who held the title VP-marketing, Dec. 1 following the unsealing of a qui tam lawsuit in which Rost alleges Pharmacia promoted the human growth hormone product Genotropin off-label prior to Pifzer's acquisition of the company in 2003 (1"The Pink Sheet" Dec. 5, 2005, In Brief). The Boston U.S. Attorney chose not to intervene in the lawsuit. Rost has been an outspoken advocate of pharmaceutical importation...

You may also be interested in...



Pfizer fires “rogue” exec

Pfizer terminates VP-Marketing Peter Rost Dec. 1. Rost made headlines in 2004 when he publicly voiced support for pharmaceutical importation (1"The Pink Sheet" Sept. 27, 2004, p. 15). His termination follows the unsealing of a qui tam lawsuit in which Rost alleged Pharmacia violated the False Claims Act by promoting the human growth hormone product Genotropin off-label prior to Pfizer's acquisition of the firm in 2003. The Boston U.S. Attorney chose not to intervene on Rost's behalf in the case although governmental investigations into other aspects of Pharmacia's Genotropin promotion are ongoing, the company says...

Cosmetics Europe Talks Microplastic: ECHA Frustrations, ‘Value Judgments’ And International Trade Uncertainty

The European Chemicals Agency's microplastic restriction proposal received committee backing in 2020 without changes sought by the cosmetics industry, which faces €15bn in projected costs and scarce alternatives at present. It may come down to EU Member States to decide whether the ECHA restriction proposal is proportionate in balancing environmental goals and socio-economic impacts.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel